Cargando…

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

BACKGROUND: Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure. The objective of this study was to investigate the real-world ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ger, Tzong-Yun, Huang, Yu-Huei, Hui, Rosaline Chung-yee, Tsai, Tsen-Fang, Chiu, Hsien-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472156/ https://www.ncbi.nlm.nih.gov/pubmed/31024679 http://dx.doi.org/10.1177/2040622319843756

Ejemplares similares

Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study
por: Foley, Peter, et al.
Publicado: (2022)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

Stratified Medicine and Reimbursement Issues
por: Fugel, Hans-Joerg, et al.
Publicado: (2012)

Real‐world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety
por: Asawanonda, Pravit, et al.
Publicado: (2022)

Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Secukinumab in Erythrodermic Psoriasis: Real World Experience of 6 Patients Successfully Treated by Injecting at Unconventional Sites
por: Panda, Maitreyee, et al.
Publicado: (2021)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
por: Crowley, Jeffrey J., et al.
Publicado: (2022)

The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies
por: Wu, Chen-Yu, et al.
Publicado: (2019)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
por: Zhang, Jing, et al.
Publicado: (2020)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang, Eric J, et al.
Publicado: (2018)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
por: Strober, Bruce, et al.
Publicado: (2022)

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
por: Megna, Matteo, et al.
Publicado: (2022)

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
por: Li, Gaojie, et al.
Publicado: (2022)

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study
por: Ding, Yangfeng, et al.
Publicado: (2023)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Secukinumab for psoriasis in a patient with familial Mediterranean fever
por: Cannavò, Serafinella P., et al.
Publicado: (2019)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
por: Tiberio, Rossana, et al.
Publicado: (2019)

Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
por: Körber, Andreas, et al.
Publicado: (2021)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
por: Narbutt, Joanna, et al.
Publicado: (2023)

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
por: Hung, Yi-Teng, et al.
Publicado: (2021)

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
por: Pariser, David, et al.
Publicado: (2017)

Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study()
por: Oguz Topal, Ilteris, et al.
Publicado: (2022)

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study
por: Galica, Katarzyna, et al.
Publicado: (2020)

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study
por: Pellegrini, Cristina, et al.
Publicado: (2022)

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab
por: Giuseppe, Pistone, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
por: Johar, Asmah, et al.
Publicado: (2019)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bl0bb764ekvuahjo9uvtln1aac